F6T Stock Overview
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Fate Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.07 |
| 52 Week High | US$7.59 |
| 52 Week Low | US$1.58 |
| Beta | 1.68 |
| 1 Month Change | -37.48% |
| 3 Month Change | -3.10% |
| 1 Year Change | -23.05% |
| 3 Year Change | -94.61% |
| 5 Year Change | -72.23% |
| Change since IPO | -19.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| F6T | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -17.3% | -1.2% | 1.7% |
| 1Y | -23.1% | -23.0% | 2.3% |
Return vs Industry: F6T matched the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: F6T underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| F6T volatility | |
|---|---|
| F6T Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: F6T's share price has been volatile over the past 3 months.
Volatility Over Time: F6T's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 181 | J. Wolchko | www.fatetherapeutics.com |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors.
Fate Therapeutics, Inc. Fundamentals Summary
| F6T fundamental statistics | |
|---|---|
| Market cap | €456.38m |
| Earnings (TTM) | -€150.07m |
| Revenue (TTM) | €59.24m |
7.7x
P/S Ratio-3.0x
P/E RatioIs F6T overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| F6T income statement (TTM) | |
|---|---|
| Revenue | US$63.53m |
| Cost of Revenue | US$161.70m |
| Gross Profit | -US$98.16m |
| Other Expenses | US$62.77m |
| Earnings | -US$160.93m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.41 |
| Gross Margin | -154.51% |
| Net Profit Margin | -253.30% |
| Debt/Equity Ratio | 0% |
How did F6T perform over the long term?
See historical performance and comparison